The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials
Abstract
BACKGROUND The Cardiovascular safety of testosterone replacement therapy (TRT) among men with hypogonadism is not well established to date. Hence, we sought to evaluate the cardiovascular disease (CVD) outcomes among patients receiving testosterone therapy by using all recently published randomized controlled trials. METHODS We performed a systematic literature search on PubMed, EMBASE, and Clinicaltrial.gov for relevant randomized controlled trials (RCTs) from inception until September 30th, 2023. RESULTS A total of 30 randomized trials with 11,502 patients were included in the final analysis. The mean age was ranging from 61.61 to 61.82 years. Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI: 0.77-1.62), P = 0.55), stroke (OR, 1.01 (95%CI: 0.68-1.51), P = 0.94), myocardial infarction (OR, 1.05 (95%CI: 0.76-1.45), P = 0.77), all-cause mortality (OR, 0.94 (95%CI: 0.76-1.17), P = 0.57), and CVD mortality (OR, 0.87 (95%CI: 0.65-1.15), P = 0.31) was comparable between TRT and placebo groups. CONCLUSION Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Male hypogonadism, resulting in low serum testosterone concentrations, has been associated with an adverse metabolic phenotype and even increased mortality (174-176).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [175]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003583 · Cited by 5,148
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Basics of meta‐analysis: I 2 is not an absolute measure of heterogeneity
Borenstein, M., Higgins, J. P. T., Hedges, L. V., & Rothstein, H. R. (2017) · Research Synthesis Methods · doi:10.1002/jrsm.1230 · Cited by 1,848
Adverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men
Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., Fraumeni, J. F., & Hoover, R. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085805 · Cited by 735
Prevalence of Symptomatic Androgen Deficiency in Men
Araujo, A. B., Esche, G. R., Kupelian, V., O’Donnell, A. B., Travison, T. G., Williams, R. E., Clark, R. V., & McKinlay, J. B. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1245 · Cited by 720
Srinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D. L., Adams, J. E., Oldham, J. A., & Wu, F. C. W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1251 · Cited by 629
DHEA in elderly women and DHEA or testosterone in elderly men.
Nair, K. S., Rizza, R. A., O'Brien, P., Dhatariya, K., Short, K. R., Nehra, A., Vittone, J. L., Klee, G. G., Basu, A., Basu, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054629 · Cited by 566
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., et al. (2011) · Diabetes Care · doi:10.2337/dc10-1233 · Cited by 548
Emmelot-Vonk, M. H., Verhaar, H. J. J., Nakhai Pour, H. R., Aleman, A., Lock, T. M. T. W., Bosch, J. L. H. R., Grobbee, D. E., & van der Schouw, Y. T. (2008) · JAMA · doi:10.1001/jama.2007.51 · Cited by 518
Research works printed but not linked: 43
- Hagi, 2021, Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and Meta-analysis, JAMA Psychiatry, 78, 510, 10.1001/jamapsychiatry.2021.0015 · DOI · Paper page
- Kloner, 2016, Testosterone and cardiovascular disease, J Am Coll Cardiol, 67, 545, 10.1016/j.jacc.2015.12.005 · DOI · Paper page
- Gandaglia, 2014, The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study, BJU Int, 114, E82, 10.1111/bju.12732 · DOI
- Alibhai, 2009, Impact of androgen deprivation therapy on cardiovascular disease and diabetes, J Clin Oncol Off J Am Soc Clin Oncol, 27, 3452, 10.1200/JCO.2008.20.0923 · DOI · Paper page
- Angell, 2012, Anabolic steroids and cardiovascular risk, Sports Med Auckl NZ, 42, 119, 10.2165/11598060-000000000-00000 · DOI
- Elagizi, 2018, Testosterone and cardiovascular health, Mayo Clin Proc, 93, 83, 10.1016/j.mayocp.2017.11.006 · DOI
- Elagizi, 2024, Testosterone and cardiovascular health, Eur Heart J, 45, 139, 10.1093/eurheartj/ehad513 · DOI
- Krishnan, 2024, Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men, Prog Cardiovasc Dis, 10.1016/j.pcad.2024.02.015 · DOI
- Jaiswal, 2024, Association between catheter ablation and dementia among patients with atrial fibrillation: a systematic review and meta-analysis, Curr Probl Cardiol, 49
- Jaiswal, 2023, Percutaneous coronary intervention versus coronary artery bypass grafting among patients with left ventricular systolic dysfunction: a systematic review and meta-analysis, Ann Med Surg, 85, 2849, 10.1097/MS9.0000000000000634 · DOI
- Jaiswal, 2023, Association between heart failure and incidence of cancer: a systematic review and meta-analysis, J Am Coll Cardiol, 81
- Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med, 21, 1539, 10.1002/sim.1186 · DOI · Paper page
- Lincoff, 2023, Cardiovascular safety of testosterone-replacement therapy, N Engl J Med, 389, 107, 10.1056/NEJMoa2215025 · DOI · Paper page
- Malkin, 2006, Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial, Eur Heart J, 27, 57, 10.1093/eurheartj/ehi443 · DOI · Paper page
- Kenny, 2010, Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty, J Am Geriatr Soc, 58, 1134, 10.1111/j.1532-5415.2010.02865.x · DOI · Paper page
- Snyder, 2001, Effect of transdermal testosterone treatment on serum lipid and apolipoprotein levels in men more than 65 years of age, Am J Med, 111, 255, 10.1016/S0002-9343(01)00813-0 · DOI
- Behre, 2012, Aging Male Off J Int Soc Study Aging Male, 15, 198, 10.3109/13685538.2012.699562 · DOI
- Hackett, 2014, The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study), Int J Clin Pract, 68, 203, 10.1111/ijcp.12235 · DOI
- Svartberg, 2004, Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial, Respir Med, 98, 906, 10.1016/j.rmed.2004.02.015 · DOI
- Amory, 2004, Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone, J Clin Endocrinol Metab, 89, 503, 10.1210/jc.2003-031110 · DOI · Paper page
- Gianatti, 2014, Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial, Diabetes Care, 37, 2098, 10.2337/dc13-2845 · DOI · Paper page
- Aversa, 2010, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study, J Sex Med, 7, 3495, 10.1111/j.1743-6109.2010.01931.x · DOI · Paper page
- Aversa, 2010, Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome, J Endocrinol Invest, 33, 776, 10.1007/BF03350341 · DOI
- Merza, 2006, Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism, Int J Androl, 29, 381, 10.1111/j.1365-2605.2005.00612.x · DOI
- Crawford, 2003, Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment, J Clin Endocrinol Metab, 88, 3167, 10.1210/jc.2002-021827 · DOI · Paper page
- Barnouin, 2021, Testosterone replacement therapy added to intensive lifestyle intervention in older men with obesity and hypogonadism, J Clin Endocrinol Metab, 106, e1096, 10.1210/clinem/dgaa917 · DOI
- Kalinchenko, 2010, Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study, Clin Endocrinol (Oxf), 73, 602, 10.1111/j.1365-2265.2010.03845.x · DOI · Paper page
- Kaufman, 2012, One-year efficacy and safety study of a 1.62% testosterone gel in Hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study, J Sex Med, 9, 1149, 10.1111/j.1743-6109.2011.02630.x · DOI
- Navarro-Peñalver, 2018, Testosterone replacement therapy in deficient patients with chronic heart failure: a randomized double-blind controlled pilot study, J Cardiovasc Pharmacol Ther, 23, 543, 10.1177/1074248418784020 · DOI
- Legros, 2009, Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study, Eur J Endocrinol, 160, 821, 10.1530/EJE-08-0634 · DOI
- Morgentaler, 2016, Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions, Mayo Clin Proc, 91, 881, 10.1016/j.mayocp.2016.04.007 · DOI
- Alexander, 2017, Cardiovascular risks of exogenous testosterone use among men: a systematic review and Meta-analysis, Am J Med, 130, 293, 10.1016/j.amjmed.2016.09.017 · DOI
- Wallis, 2016, Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study, Lancet Diabetes Endocrinol, 4, 498, 10.1016/S2213-8587(16)00112-1 · DOI · Paper page
- Sardar, 2023, Identification of novel biomarkers for early diagnosis of atherosclerosis using high-resolution metabolomics, Metabolites, 13, 1160, 10.3390/metabo13111160 · DOI
- Cai, 2014, Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials, Asian J Androl, 16, 146, 10.4103/1008-682X.122346 · DOI
- Webb, 2008, Effects of oral testosterone treatment on myocardial perfusion and vascular function in men with low plasma testosterone and coronary heart disease, Am J Cardiol, 101, 618, 10.1016/j.amjcard.2007.09.114 · DOI
- Gagliano-Jucá, 2017, Effects of testosterone replacement on electrocardiographic parameters in men: findings from two randomized trials, J Clin Endocrinol Metab, 102, 1478, 10.1210/jc.2017-00196 · doi:10.1210/jc.2017-00196
- Gagliano-Jucá, 2018, Androgen deprivation therapy is associated with prolongation of QTc interval in men with prostate cancer, J Endocr Soc, 2, 485, 10.1210/js.2018-00039 · DOI
- Al-Qudimat, 2021, Testosterone treatment improves liver function and reduces cardiovascular risk: a long-term prospective study, Arab J Urol, 19, 376, 10.1080/2090598X.2021.1959261 · DOI
- Kaur, 2021, The effect of testosterone on cardiovascular disease and cardiovascular risk factors in men: a review of clinical and preclinical data, CJC Open, 3, 1238, 10.1016/j.cjco.2021.05.007 · DOI
- Oh, 2022, Sex hormones and the risk of cardiovascular disease and mortality in male and female patients with chronic kidney disease: a systematic review and meta-analysis, Physiol Rep, 10, 10.14814/phy2.15490 · DOI
- Gagliano-Jucá, 2019, Testosterone replacement therapy and cardiovascular risk, Nat Rev Cardiol, 16, 555, 10.1038/s41569-019-0211-4 · DOI · Paper page
- Blackwell, 2023, Testosterone replacement therapy and cardiovascular disease: balancing safety and risks in Hypogonadal men, Curr Cardiol Rep, 25, 1157, 10.1007/s11886-023-01935-1 · DOI
Cited by
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Metadata
- Authors
- Jaiswal, V., Sawhney, A., Nebuwa, C., Borra, V., Deb, N., Halder, A., Rajak, K., Jha, M., Wajid, Z., Thachil, R., Bandyopadhyay, D., Mattumpuram, J., & Lavie, C. J.
- Venue
- Progress in Cardiovascular Diseases
- Publisher
- Elsevier BV
- Published
- 2024-07
- Volume
- 85
- Pages
- 45-53
- ISSN
- 0033-0620
- Cited by
- 30
- References
- 24
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. https://app.cochat.ai/papers/10.1016/j.pcad.2024.04.001
- The paper
- Jaiswal, V., Sawhney, A., Nebuwa, C., Borra, V., Deb, N., Halder, A., Rajak, K., Jha, M., Wajid, Z., Thachil, R., Bandyopadhyay, D., Mattumpuram, J., & Lavie, C. J. (2024). Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. Progress in Cardiovascular Diseases. https://doi.org/10.1016/j.pcad.2024.04.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.